The ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer.
about
Estrogen and xenoestrogens in breast cancerMicroRNA-21 targets Sprouty2 and promotes cellular outgrowthsExpression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomasLoss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to HerceptinMicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligandThe expression of the Sprouty 1 protein inversely correlates with growth, proliferation, migration and invasion of ovarian cancer cellsThe developing story of Sprouty and cancer.Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapyFunctional interaction between Env oncogene from Jaagsiekte sheep retrovirus and tumor suppressor Sprouty2.Sprouty1, a new target of the angiostatic agent 16K prolactin, negatively regulates angiogenesis.Hypoxia and nickel inhibit histone demethylase JMJD1A and repress Spry2 expression in human bronchial epithelial BEAS-2B cells.Feedback regulations of miR-21 and MAPKs via Pdcd4 and Spry1 are involved in arsenite-induced cell malignant transformationExpression and functional role of sprouty-2 in breast morphogenesis.SPRY1 promotes the degradation of uPAR and inhibits uPAR-mediated cell adhesion and proliferationNegative Regulation of Receptor Tyrosine Kinase (RTK) Signaling: A Developing FieldModulation of fibroblast growth factor signaling is essential for mammary epithelial morphogenesis.Sprouty is a cytoplasmic target of adenoviral E1A oncoproteins to regulate the receptor tyrosine kinase signalling pathwayRegulation of cellular levels of Sprouty2 protein by prolyl hydroxylase domain and von Hippel-Lindau proteinsPI3K signaling and miRNA expression during the response of quiescent human fibroblasts to distinct proliferative stimuli.Sprouty 1 predicts prognosis in human epithelial ovarian cancerEndometrial Cancer and Hypermethylation: Regulation of DNA and MicroRNA by EpigeneticsAssessment of Tumor Heterogeneity, as Evidenced by Gene Expression Profiles, Pathway Activation, and Gene Copy Number, in Patients with Multifocal Invasive Lobular Breast Tumors.Sprouty is a negative regulator of transforming growth factor β-induced epithelial-to-mesenchymal transition and cataract.Hypoxia inducible factors regulate the transcription of the sprouty2 gene and expression of the sprouty2 proteinFibrosis in the lens. Sprouty regulation of TGFβ-signaling prevents lens EMT leading to cataract.Initial report on differential expression of sprouty proteins 1 and 2 in human epithelial ovarian cancer cell lines.Targeting the ERK signaling pathway in cancer therapy.Aberrant expression of hSef and Sprouty4 in endometrial adenocarcinoma.ERK MAP kinase in G cell cycle progression and cancer.Suppression of Spry1 inhibits triple-negative breast cancer malignancy by decreasing EGF/EGFR mediated mesenchymal phenotype.c-MYC-regulated miR-23a/24-2/27a cluster promotes mammary carcinoma cell invasion and hepatic metastasis by targeting Sprouty2.(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway.Overexpression of Sprouty 2 in mouse lung epithelium inhibits urethane-induced tumorigenesisSprouty2 interacts with protein kinase C delta and disrupts phosphorylation of protein kinase D1.Intermolecular interactions of Sprouty proteins and their implications in development and disease.ARF1 promotes prostate tumorigenesis via targeting oncogenic MAPK signaling.The FRS2 family of docking/scaffolding adaptor proteins as therapeutic targets of cancer treatment.The role of fibroblast growth factors in tumor growthSprouty2 correlates with favorable prognosis of gastric adenocarcinoma via suppressing FGFR2-induced ERK phosphorylation and cancer progression.Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response.
P2860
Q24605175-79D7F09C-8382-40A6-AE68-07A11EC42CFBQ24653709-E020ED6E-997E-4419-BDDF-D6B0DE5A69E9Q24657474-7E287981-E291-49E5-9892-5589E21A75A7Q28247112-7A0729EA-2618-436D-867D-52C51E4D83CAQ28509297-2D33E072-CAB4-48A7-8610-C85CCBD1D625Q33756953-296FE864-D9B7-4375-92E9-99DA02639333Q33962853-418AADF7-39C6-4C3F-81E4-76A9EA17A832Q34016357-CC3ECD50-C688-4C61-B52D-3FE854E70C4EQ34067681-270AB93D-F30D-473F-A506-7CC4C3644B52Q34152172-B754FF1A-AF48-48BD-8565-4FA9DE3801B0Q34363873-F693468C-50F0-44E2-AF44-7090E9E43442Q34613149-77FA9608-767B-457D-AF1E-40741FE3926EQ34662115-891CB63B-6FA6-41F8-9C37-5D20016CA61BQ34704836-DA484A0D-7A96-4C1B-8FD3-B8F614A08DB4Q34996130-20BFEF83-22F2-4A58-81AE-0FD270412671Q35144000-F4BF093D-D9FC-4A6A-AB2E-23F5A3641C2BQ35154608-736F95A3-2332-49E3-82C0-37A7B7990649Q35604936-A0172A7E-A2F6-4CA7-AADA-B9DCC88E9FD6Q35605939-8951A685-68D5-4CA3-9728-189A195DB194Q35758025-7FFDB3D0-562D-433D-8450-EE71DA8BF1B7Q35882785-AF5B2223-83D7-4722-A0AB-99FB7D341153Q35990106-9860FA2E-E9F4-4E29-923B-3D8AF685D0B2Q36130909-0C2D4451-3371-4745-817A-A9B5CE8F953BQ36280143-845D460D-BD74-4221-BB07-11F0A4FE6A26Q36303720-A7481417-2CA2-4B0E-8279-60E7FD769C6FQ36454937-A732C690-5053-4FF1-B8C8-01745C798124Q36486780-CDFEF77B-B77E-4454-9B87-2E96B1903A46Q36502806-687A6250-5851-4119-916A-09FDD3D7DD8DQ36519437-9000DFB1-5FEA-455D-A014-85A9F327BFE6Q36686648-8A0120AD-CD8C-48F7-B7FE-FE2E7DA908D1Q36947761-C7AB3ACE-185F-4075-995A-54C72B0FC2C0Q37112466-1994F292-44FE-40B5-A14B-FAE74CB7B655Q37287148-ABAA90AE-0ACC-4DD8-9E6C-9DAD4DE5A6D3Q37339363-FEAA04BF-46D1-438F-8A9F-C8B12B9160A0Q37402776-9AD263C2-1AB4-4EDC-BA60-6E46E94BE960Q37457689-45C9A160-601F-489C-9151-8BF961627E4DQ37489930-4C4E4144-D7D0-4AD1-AE33-C8F089F338E8Q37512303-B76F39E1-0442-4B32-9C91-3006260BB120Q37706271-E88C53D2-5797-4E90-A843-B2D34C38C76CQ37753517-8B3AE18B-873D-4973-9056-43386AC312C6
P2860
The ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The ras/mitogen-activated prot ...... deregulated in breast cancer.
@en
type
label
The ras/mitogen-activated prot ...... deregulated in breast cancer.
@en
prefLabel
The ras/mitogen-activated prot ...... deregulated in breast cancer.
@en
P2093
P1433
P1476
The ras/mitogen-activated prot ...... e deregulated in breast cancer
@en
P2093
Ben J McCaw
Chee Wai Fong
Esther Sook Miin Wong
Graeme R Guy
Hwei Fen Leong
Permeen Yusoff
Thomas Choudary Putti
P304
P356
10.1158/0008-5472.CAN-04-1207
P407
P577
2004-09-01T00:00:00Z